Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 2/20 | 0.30 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.30 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25166912 | 0.91 | CHRM2 (0.32) | TRPV1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL30270924 | 0.88 | CHRM2 (0.32) | TRPV1CASP3SENP8SENP7SENP6 | |
| SCHEMBL31509913 | 0.84 | TRPV1 (0.31) | TRPV1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL30393112 | 0.83 | PKM (0.32) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL25683931 | 0.83 | PKM (0.32) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL31509780 | 0.80 | PTK2 (0.30) | HTT | |
| SCHEMBL31509752 | 0.79 | — | — | |
| SCHEMBL31509778 | 0.79 | — | — | |
| SCHEMBL31509886 | 0.77 | RXRA (0.30) | — | |
| SCHEMBL23692294 | 0.76 | TACR1 (0.35) | TRPV1CASP3SENP8SENP7SENP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127801-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2025080850-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127801-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DPYD | TRPV1 3404/4885CASP3 348/4885SENP8 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.